BeOne Medicines ((ONC)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: BeOne Medicines is conducting a Phase 1 clinical study titled ‘A Phase 1, Single-dose, Open-label, Randomized, Crossover Study in Healthy Adult Participants to Evaluate Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332)’. The study aims to assess the bioavailability of a new combination tablet compared to separate administration of its components, and how food affects its absorption. This research is significant as it may lead to more efficient drug delivery methods.
Intervention/Treatment: The study tests a fixed-dose combination tablet, BG-71332, containing zanubrutinib and sonrotoclax. These drugs are intended to be administered orally to evaluate their combined effect and absorption under different dietary conditions.
Study Design: This is an interventional study with a randomized, sequential model. It is open-label, meaning no masking is involved, and the primary purpose is to explore bioavailability and food effects in healthy volunteers.
Study Timeline: The study is not yet recruiting, with the initial submission date on August 19, 2025. The primary completion and estimated completion dates are not yet available, indicating the study is in its early stages.
Market Implications: This study could impact BeOne Medicines’ stock performance positively if the results show improved drug delivery, potentially enhancing investor confidence. In the competitive pharmaceutical industry, successful outcomes could position BeOne Medicines favorably against competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.